Journal of Clinical Oncology
Articles in this Issue
Effect of nimotuzumab addition to neoadjuvant chemotherapy in pancreatic carcinoma: A retrospective study.
e16357 Background: Current conversion treatment regimens including gemcitabine-based therapy and 5FU-based chemotherapy have a limited rate of conversion...
Limited changes in the CNS immune microenvironment in patients with breast cancer metastasis and capturing these changes using machine learning.
1092 Background: Metastasis of breast cancer to the central nervous system (CNS) is common, especially in triple negative and HER2-positive tumors. The CN...
Efficacy and safety of asciminib (ASC) in patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) after 1 tyrosine kinase inhibitor (TKI): Interim analysis (IA) of the phase 2 ASC2ESCALATE trial.
6516 Background: ASC2ESCALATE (NCT05384587) is the first prospective trial of ASC in CML-CP after 1 TKI (2L) with dose escalation for pts with suboptimal...
LAPNet1: Phase 1b study investigating the association of NP137 with mFOLFIRINOX in locally advanced pancreatic ductal adenocarcinoma.
e16441 Background: Pancreatic ductal adenocarcinoma is one of the most lethal malignancies with a 5-year survival rate under 5%. Locally advanced pancreat...
Access to cancer care for undocumented immigrants in the United States.
11034 Background: Undocumented immigrants represent a disproportionate share of uninsured individuals in the United States, owing to federal restrictions...
Landscape analysis of proteins in the development of breast cancer brain metastasis.
1050 Background: Breast cancer brain metastasis(BCBM) is a major cause of mortality in advanced breast cancer patients, and treatment options are limited....
Overall survival based on sequencing of fruquintinib, regorafenib, and TAS-102 with or without bevacizumab in treatment-refractory metastatic colorectal cancer.
e15527 Background: Fruquintinib, regorafenib, and trifluridine-tipiracil (TAS-102) alone or in combination with bevacizumab (bev) are approved for use in...
A retrospective study of characteristics and outcome of immune checkpoint inhibitor renal toxicities in a pan-cancer cohort of patients.
e14608 Background: Renal toxicities is a known side effect of immune checkpoint inhibitors (ICI). However, our understanding of the predisposing factors a...
An exploratory analysis of myelofibrosis (MF) patient subgroups by baseline hemoglobin levels in the gecacitinib phase 3 trial.
6571 Background: Anemia is a key prognostic indicator of MF. In the double-blind, randomized phase 3 ZGJAK016 trial, gecacitinib (GCA), a dual JAK/ACVR1 i...
First report of efficacy and safety results from a phase 2 trial evaluating BNT327/PM8002 plus chemotherapy (chemo) as first-line treatment (1L) in unresectable malignant mesothelioma.
8511 Background: Malignant mesothelioma is a rare neoplasm with a high unmet medical need. BNT327 is an investigational bispecific antibody, targeting bot...
Unveiling the unheard narratives: Integrating narrative medicine into electronic medical records for non–English-speaking cancer patients.
e23132 Background: In recent years, narrative medicine has gained traction in medical practice, enabling patients with cancer to affirm their self-worth a...
Neoadjuvant immunotherapy of hepatocellular carcinoma: A single-institution experience at Mount Sinai.
e16320 Background: Immunotherapy has markedly improved the survival of patients with advanced hepatocellular carcinoma (HCC). Early-stage HCC is potential...
Real-world experience with vorasidenib in IDH-mutant gliomas: Tolerability, adverse events, and access in patients who did not meet INDIGO trial eligibility criteria.
e14029 Background: Vorasidenib was FDA-approved for the treatment of IDH-mutant grade 2 glioma in August 2024, largely on the basis of positive results fr...
Meta-analysis of the efficacy of CDK4/6 inhibition in the management of metastatic HER2+/HR+ breast cancer.
e13001 Background: HER2+/HR+ breast cancer accounts for approximately 10% of all breast cancers and is often associated with CNS and visceral metastases....
Efficacy and safety of different PD-1 inhibitors combined with chemotherapy in locally advanced head and neck squamous cell carcinoma.
e18114 Background: Surgery or definitive chemoradiotherapy are mainstay treatment of locally advanced head and neck squamous cell carcinoma (HNSCC). The h...
Improving access to cancer screening through national telehealth-based lung and colorectal cancer screening programs.
1549 Background: Access to routine cancer screening remains a significant barrier to early detection, especially among historically underserved population...
Validation of the HFA-ICOS cardiovascular toxicity risk tool in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors: Real-world data from the Saudi population.
e24009 Background: Tyrosine kinase inhibitors (TKIs) are the cornerstone treatment in patients with chronic myeloid leukem...
Outcomes of salvage radiotherapy in relapsed/refractory large B-cell lymphoma patients following CAR T-cell therapy failure.
e19007 Background: Post-CAR T relapsed/refractory disease is a significant challenge in large B-cell lymphoma (LBCL) patients. Salvage radiotherapy (SRT)...
A novel co-culture system to validate results of a phase I trial testing new treatment for Barrett’s esophagus.
e15099 Background: The role of the mesenchyme in the development of Barrett’s esophagus (BE) is largely unknown. In a Phase I trial “Tamoxifen to Treat Ba...
Risk of tumor lysis syndrome associated with kinase inhibitors: Analysis of FAERS and real-world data.
e24101 Background: Tumor lysis syndrome (TLS) is an oncological emergency caused by rapid tumor cell breakdown leading to the swift release of intracellul...
Transcriptomic landscape of Kaposi sarcoma: Insights into therapeutic targeting of KSHV.
e23526 Background: Kaposi sarcoma (KS) is a tumor caused by Kaposi sarcoma herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8). Unlike other vir...
Molecular correlates of response in patients with metastatic castration-resistant prostate cancer treated with olaparib with or without cediranib (NCI9984).
5080 Background: The phase 2 NCI 9984 study (NCT02893917) randomized patients with progressive metastatic castration resistant prostate cancer (mCRPC) 1:1...
Prognostic factors for brain metastasis in adolescent and young adult patients.
e14011 Background: Adolescents and young adults (AYA), aged 15 to 39 at diagnosis, account for 2% of invasive cancers in US. Despite significant advances...
Correlation between circulating tumor DNA (ctDNA) and disease status in soft tissue sarcoma patients: A pilot study.
e23559 Background: Circulating tumor DNA (ctDNA) is used to monitor minimal residual disease (MRD), treatment response, and recurrence in patients with so...
Risk of invasive fungal infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors: A TriNetX-based retrospective cohort study from 2000-2025.
7035 Background: Chronic lymphocytic leukemia (CLL) is associated with immunosuppression, and Bruton tyrosine kinase inhibitors (BTKis) may further increa...